Spero Therapeutics, Inc.
SPRO
$0.71
-$0.0152-2.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 47.98M | 106.46M | 118.46M | 110.98M | 103.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.98M | 106.46M | 118.46M | 110.98M | 103.78M |
| Cost of Revenue | 134.27M | 91.19M | 91.11M | 76.90M | 68.54M |
| Gross Profit | -71.25M | 15.26M | 27.35M | 34.08M | 35.24M |
| SG&A Expenses | 23.70M | 23.08M | 23.59M | 24.15M | 25.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 120.46M | 107.56M | 97.60M | 83.95M | 76.99M |
| Operating Income | -72.48M | -1.10M | 20.86M | 27.03M | 26.79M |
| Income Before Tax | -68.57M | 3.61M | 20.05M | 26.00M | 25.40M |
| Income Tax Expenses | 0.00 | 97.00K | 2.60M | 2.60M | 2.60M |
| Earnings from Continuing Operations | -68.57 | 3.51 | 17.46 | 23.40 | 22.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.57M | 3.51M | 17.46M | 23.40M | 22.81M |
| EBIT | -72.48M | -1.10M | 20.86M | 27.03M | 26.79M |
| EBITDA | -72.39M | -973.30K | 21.10M | 27.38M | 27.15M |
| EPS Basic | -1.27 | 0.08 | 0.34 | 0.44 | 0.43 |
| Normalized Basic EPS | -0.78 | 0.05 | 0.30 | 0.37 | 0.36 |
| EPS Diluted | -1.27 | 0.08 | 0.33 | 0.44 | 0.42 |
| Normalized Diluted EPS | -0.78 | 0.05 | 0.30 | 0.37 | 0.36 |
| Average Basic Shares Outstanding | 216.15M | 214.61M | 213.19M | 211.81M | 210.81M |
| Average Diluted Shares Outstanding | 216.15M | 214.72M | 213.30M | 211.91M | 210.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |